Health care stocks climbed late Monday afternoon with the NYSE Health Care Index up 0.5% and the Health Care Select Sector SPDR Fund (XLV) rising 0.8%.
The iShares Biotechnology ETF (IBB) climbed 1.3%.
In corporate news, Unity Biotechnology (UBX) shares fell 28%. The company's UBX1325, the diabetic macular edema treatment for patients with poor vision, didn't achieve statistical non-inferiority at the primary analysis endpoint in a phase 2b trial.
TransCode Therapeutics (RNAZ) shares dropped 38%. The company agreed to sell shares to raise $10 million.
23andMe (ME) filed for Chapter 11 bankruptcy protection to help facilitate a potential sale, while Anne Wojcicki resigned as chief executive officer, less than a month after she attempted to buy the genetic testing firm. 23andMe shares tumbled 59%.
Novo Nordisk (NVO) secured exclusive global rights to United Laboratories International's therapeutic candidate for obesity and type 2 diabetes in a licensing deal worth up to $2 billion. Novo shares shed 2%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。